ViziosoF., AllendeMaT, FueyoA., VigalG., García MoranM., RuibalA.CA 15.3 behaviour in patients with breast cystic diseases.Int J Biol Markers1989; 4: 181–2.
2.
VizosoF., AllendeMaT, FueyoA., VivancoJ.Correlación entre las concentraciones séricas de CA15.3 y estradiol en mujeres afectas de enfermedad macro-quística de la mama.Med Clin1990; 84: 789.
3.
VizosoF., AllendeMaT, DiezMaC, RuibalA.Evidence of a correlation between CA 15.3 and estradiol serum levels in women with fibrocystic (non macrocysts) mastopathy.Int J Biol Markers (in press).
4.
KumarS., ManselR.E., HuglesL.E.Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease.Cancer1984; 53: 1311–5.
5.
PetersF., SchulhW., ScheurichB., BreckwoltN.Serum prolactin levels in patients with fibrocystic breast disease.Obstet Gynecol1984; 64: 381–5.
